Pepticom is pleased to announce that Pierre Riviere, Ph.D., has joined the company’s Scientific Advisory Board to advise Pepticom on its peptide therapeutics strategy, programs and business.

Dr. Riviere has over 25 years of biopharmaceutical industry experience with R&D leadership roles in target and drug discovery, nonclinical and early-stage clinical development. He is a recognized expert in peptide therapeutics with both established peptide modalities and emerging novel peptide technologies. Dr. Riviere is Founder and CEO of Peptide Logic, a San Diego-based biotech company developing novel peptide therapeutic modalities. He previously was CSO at CovX, a leading peptide-antibody conjugates company; a SVP of Pfizer worldwide R&D and member of the Pfizer Leadership Team; and SVP Research at Ferring Pharmaceuticals, a leading peptide therapeutics company. He is also a co-founder of Cara Therapeutics and the Peptide Therapeutics Foundation and the Annual Peptide Therapeutics Symposium. Dr. Riviere received a Ph.D. in animal physiology and biology from the Institut National Polytechnique, Toulouse, and completed postdoctoral studies at the University of Arizona, Tucson.

Skip to content